HHLR ADVISORS, LTD.'s Net Worth

$22.8 Billion

Estimate Recalculated Feb 7, 2024 04:05PM EST

Who is HHLR ADVISORS, LTD.?

HHLR ADVISORS, LTD. has an estimated net worth of $22.8 Billion. This is based on reported shares across multiple companies, which include ArriVent Biopharma, Inc., BeiGene, Ltd., and Cellular Biomedicine Group, Inc..

SEC CIK

HHLR ADVISORS, LTD.'s CIK is 0001762304

Past Insider Trading and Trends

2024 was HHLR ADVISORS, LTD.'s most active year for acquiring shares with 3 total transactions. HHLR ADVISORS, LTD.'s most active month to acquire stocks was the month of December. 2023 was HHLR ADVISORS, LTD.'s most active year for disposing of shares, totalling 8 transactions. HHLR ADVISORS, LTD.'s most active month to dispose stocks was the month of May. 2024 saw HHLR ADVISORS, LTD. paying a total of $9,999,990.00 for 4,484,672 shares, this is the most they've acquired in one year. In 2023 HHLR ADVISORS, LTD. cashed out on 4,154,817 shares for a total of $823,490,197.76, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

ArriVent Biopharma, Inc. No price found

Investor

HHLR ADVISORS, LTD. owns 4,484,672 units of Common Stock. In the year 2024 HHLR ADVISORS, LTD. filed a total of 1 filing.

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
4.48M
$18.00
4.48M
Jan 30
No matching records found

BeiGene, Ltd. (BGNE) Snapshot price: $153.58

Investor

HHLR ADVISORS, LTD. owns 142,888,241 units of Ordinary Shares which is worth $21,944,776,052.78. From 2020 to 2023 HHLR ADVISORS, LTD. acquired a total of 7,800 shares in BeiGene, Ltd., HHLR also disposed a total of 4,154,817 shares of BeiGene, Ltd. equalling to $823,490,197.76.

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-0.83%
-1.20M
$188.88
-$226,306,339.45
142.89M
Jun 13 - Jun 14
Form 4
-2.01%
-2.96M
$201.98
-$597,183,858.31
144.09M
Jun 8 - Jun 12
Form 4
+0.01%
7.8K
147.04M
Aug 22
Form 3
0
0
No matching records found

Cellular Biomedicine Group, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 3
0
0
No matching records found